ACPU
AEGR

Arrowgrass Capital Partners (US)’s Aegerion Pharmaceuticals AEGR Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-60,000
Closed -$1.26M – 574
2014
Q4 		$1.26M Buy
+60,000
New +$1.51M 0.02% 286

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s AEGR Position: Q1 2015 in Review

Arrowgrass Capital Partners (US) sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2015, closing a stake of 60,000 shares — an estimated $1.26M sold.

Arrowgrass Capital Partners (US) first reported a position in AEGR in Q4 2014 and held it in 1 quarter. The position peaked at $1.26M in Q4 2014. 99 funds tracked by Wall St. Rank hold AEGR as of Q1 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Aegerion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 60,000 Aegerion Pharmaceuticals shares in Q1 2015, an estimated $1.26M.
  • Arrowgrass Capital Partners (US) first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Aegerion Pharmaceuticals position peaked at $1.26M in Q4 2014.
  • 99 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2015, filed 15 May 2015.